NewLimit, the longevity startup co-founded by Coinbase CEO Brian Armstrong, raised $435 million in fresh funding that pushes its valuation to $3.1 billion—more than triple its worth a year ago. The company has no approved products yet but is preparing to test its RNA therapy in alcohol-related liver disease patients next year.

The surge reflects growing investor enthusiasm for anti-aging therapeutics, joining a crowded field of billionaire-backed ventures. OpenAI CEO Sam Altman invested $180 million in Retro Biosciences, valued at $1.8 billion, while Altos Labs launched with $3 billion in 2022 funding reportedly from Jeff Bezos. These companies pursue drugs that could halt or reverse biological aging, a fundamentally new approach to prescription medicine.

NewLimit's strategy focuses on epigenetic reprogramming—altering DNA markings to reset cells to a younger state. By targeting liver disease first, the startup aims to gain regulatory approval before expanding to broader aging-related conditions like metabolic syndrome. Former Google Ventures partner Blake Byers and new CEO Jacob Kimmel lead this approach.

The FDA still does not recognize aging as a disease, making specific indications like liver disease essential for market entry. Success could establish a template for bringing anti-aging therapies to market, potentially reshaping pharmaceutical development and creating massive value for early investors.